First Trust DJ Microcap Index Fd

Stoke Therapeutics and Biogen Show Positive Data for Dravet Syndrome Drug

Ameresco Completes Solar Photovoltaic Project for Orange Unified School District

Tetra and Magrathea Joint Venture to Produce Magnesium and Bromine in Arkansas

Tetra Technologies Plans to Joint Venture with Magrathea to Build Magnesium Refinery

Stoke Therapeutics and Biogen to Present New Clinical Data on Zorevunersen at AES Annual Meeting

Ameresco Collaborates with Maryland Authorities to Install EV Charging Ports

Ameresco Inc. Launches $1 Million Solar Project With Chandler City

Ameresco Inc. releases new investor presentation showcasing energy solutions

HC Wainwright Cuts Stoke Therapeutics 2029 EPS Forecast

GigaCloud Tech released FY2025 Q3 earnings on November 6 After-Market (EST), actual revenue USD 332.64 M (forecast USD 300.96 M), actual EPS USD 0.99 (forecast USD 0.7233)

GigaCloud Tech released FY2025 9 Months earnings on November 6 After-Market (EST), actual revenue USD 927.15 M, actual EPS USD 2.5758

Ameresco Inc. Launches Clean Energy Projects at Goldendale Hospital

ODP released FY2025 9 Months Earnings on November 5 (EST), with actual revenue of USD 4.91 B and EPS of USD -0.25

ODP released FY2025 Q3 earnings on November 5 (EST), actual revenue USD 1.625 B (forecast USD 1.669 B), actual EPS USD 0.72 (forecast USD 0.815)

Deluxe released FY2025 Q3 earnings on November 5 After-Market EST, actual revenue USD 540.2 M (forecast USD 526.5 M), actual EPS USD 0.739 (forecast USD 0.465)

Deluxe released FY2025 9 Months Earnings on November 5 After-Market EST, actual revenue USD 1.598 B, actual EPS USD 1.5471

Stoke Therapeutics to Speak on Zorevunersen at Guggenheim Healthcare Innovation Conference

Ameresco Presents Investor Presentation Highlighting Achievements and Strategic Focus

ODP Reports Q3 Revenue Decline but Adjusted Earnings Beat Estimates

Rigel Pharma released FY2025 Q3 earnings on November 4 After-Market EST, actual revenue USD 69.46 M (forecast USD 61.88 M), actual EPS USD 1.46 (forecast USD 0.9025)

Treasure Gbl

SMX Security Matters

Wheeler Real Estate

Gulf Resources

DigitalBridge

Toro

Dreamland

Lichen

Springview

Alumis

STOK

BIIB

Stoke Therapeutics and Biogen presented positive data on zorevunersen for Dravet syndrome at the AES 2025 Meeting. The data showed increased seizure-free days and improved quality of life for patients. Further safety and efficacy data are expected from the ongoing Phase 3 EMPEROR program.

Reuters

Stoke Therapeutics

Biogen

Stoke Therapeutics and Biogen Present Positive Zorevunersen Data for Dravet Syndrome at AES 2025 Meeting

Barry Ticho, an insider at Stoke Therapeutics, sold 2,006 shares at $29.78 each, totaling $59,738.68. This sale reduced his holdings by 10.46%. Recent trades include selling 2,014 shares at $30.65 and 5,931 shares at $25.72. Stoke Therapeutics' stock rose 3.9% to $30.96. Analysts have mixed ratings, with a consensus "Buy" and an average target price of $31.00.

Market Beat

Insider Selling: Stoke Therapeutics (NASDAQ:STOK) Insider Sells 2,006 Shares of Stock

Executives at Stoke Therapeutics, including Edward M. Kaye, Barry Ticho, and Allan Jonathan, sold shares to cover tax liabilities. Kaye sold 2,136 shares for $64,541, Ticho sold 4,020 shares for $121,468, and Jonathan sold 4,576 shares for $138,268. These transactions occurred on December 2 and 3, 2025, with prices ranging from $28.93 to $31.17 per share.

TradingView

Stoke Therapeutics Executives Sell Shares to Cover Tax Liabilities and Other Reasons

Officer Ticho Barry of Stoke Therapeutics Inc filed a Form 4 with the SEC, disclosing changes in ownership. On December 1, 2025, he exercised 11,981 shares at $0.00, and between December 2-3, 2025, surrendered 4,020 shares at $30.22, valued at $121,468, to cover option exercise costs and tax liabilities. His ending holdings are 15,156 shares directly.

Officer Ticho Acquires 7,961 Of Stoke Therapeutics Inc [STOK]

Kaye Edward M, Director of Stoke Therapeutics Inc, filed a Form 4 with the SEC on December 3, 2025, disclosing changes in ownership. He exercised 4,317 shares on 12/1/24 and surrendered 2,136 shares between 12/2/25 and 12/3/25 at $30.22 per share, valued at $64,541, to cover option exercise costs and tax liabilities. His ending holdings are 51,305 shares directly.

Dir Kaye Acquires 2,181 Of Stoke Therapeutics Inc [STOK]

Officer Allan Jonathan of Stoke Therapeutics Inc filed a Form 4 with the SEC, disclosing changes in ownership. He exercised 12,357 shares and surrendered 4,576 shares to cover option exercise costs and tax liabilities, ending with 19,612 shares directly. This insider trading activity was reported on December 3, 2025.

Officer Allan Acquires 7,781 Of Stoke Therapeutics Inc [STOK]

AMRC

UBS analyst Jon Windham maintains a Hold rating on Ameresco with a $40 price target, citing its strategic positioning in clean energy and substantial backlog. Despite potential for long-term growth, the Hold rating reflects balanced valuation and market conditions. Windham's updated valuation aligns with peers' EV/EBITDA multiples, suggesting fair stock value. Windham, a 4-star analyst, has a 10.5% average return and 53.76% success rate, covering the Industrials sector.

Tip Ranks

Ameresco

Ameresco’s Strategic Positioning in Clean Energy: Hold Rating Reflects Balanced Valuation and Growth Potential

Stoke Therapeutics has seen significant stock price fluctuations, with a 164.5% increase year-to-date. Despite investor enthusiasm for its genetic medicines pipeline, valuation checks score 0/6, indicating overvaluation. A Discounted Cash Flow analysis suggests the stock is 139.8% overvalued, while its PE ratio of 42.0x is above industry averages, suggesting strong future progress but also overvaluation. The article explores valuation approaches and introduces a narrative framework for understanding Stoke's long-term value.

Simplywall

Does Stoke Therapeutics Still Make Sense After Its 2025 Rally And Lofty Valuation Multiples?

Ameresco Inc. has completed a solar photovoltaic installation project for Orange Unified School District (OUSD) in California, covering seven school campuses. Under a 25-year power purchase agreement, Ameresco will own and maintain the systems, while OUSD will buy the generated power, saving $6.3 million over the period. Five projects are complete, with the remaining two to be finished by 2025.

Ameresco Secures Solar Power Agreement with Orange Unified School District

Stoke Therapeutics and Biogen will present new analyses and findings from studies of zorevunersen for Dravet syndrome at the 2025 American Epilepsy Society Annual Meeting. Data from long-term open-label extension studies and EEG assessments suggest zorevunersen has the potential for disease modification, showing improvements in seizure frequency, behavior, and cognition. These presentations will highlight the investigational antisense oligonucleotide's impact on reducing abnormal brain activity and its overall efficacy in patients with this severe developmental and epileptic encephalopathy.

Business Wire

Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

Stoke Therapeutics Inc. and Biogen Inc. will present new clinical data on zorevunersen at the 2025 AES Annual Meeting, highlighting its disease-modifying effects in Dravet syndrome patients. The presentations will focus on seizure-free days, quality of life, overall functioning, and EEG improvements. Results will be shared in oral and poster sessions.

Stoke Therapeutics Reports Zorevunersen Shows Disease-Modifying Effects in Dravet Syndrome Study

Adrian R. Krainer, Director of Stoke Therapeutics Inc., has reported the disposal of common shares of the company. The information was published via EDGAR by the U.S. Securities and Exchange Commission on November 26, 2025. This news brief was generated by Public Technologies using AI and is for informational purposes only.

Stoke Therapeutics Director Adrian R. Krainer Reports Disposal of Common Shares

Ameresco's stock rose 6.8% following strong Q3 earnings and new data center deals. The company reported recurring revenue from energy assets exceeding 60% of EBITDA, supporting higher margins. However, it faces risks from capital-intensive development and high leverage. Recent contracts, including a 50 MW battery storage system in Arizona, highlight growth in data center energy solutions. Ameresco projects $2.4 billion revenue and $87.4 million earnings by 2028, requiring 8.8% annual revenue growth. Fair value estimates range from $36 to $81.16, with potential impacts from rising financing costs.

Why Ameresco (AMRC) Is Up 6.8% After Strong Q3 Earnings and New Data Center Deals

RIGL

Rigel Pharmaceuticals Inc. will present a company overview at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025. CFO Dean Schorno will represent the company, with a live webcast available on Rigel’s Investor Relations website. This information was originally published by Rigel Pharmaceuticals via PR Newswire.

Rigel Pharma

Rigel Pharmaceuticals to Present at Piper Sandler Healthcare Conference

Ameresco and The Resilience Authority of Annapolis and Anne Arundel County, Maryland, are collaborating to install 82 new EV charging ports across nine county-owned facilities. The project aims to reduce environmental footprints and operating costs by electrifying fleets, with a mix of Level 2 and DC fast chargers. The initiative is expected to save $350,000 annually in utility costs and reduce electrical capacity by 2.5 MW, using Ameresco's ChargePilot system for managed charging.

cleantechnica

82 New EV Charging Ports Coming To Part Of Maryland